H.C. Wainwright Reiterates Buy Rating on Vanda Pharmaceuticals (VNDA)

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $20.00 price target on Vanda Pharmaceuticals (NASDAQ: VNDA).

The analyst commented: "We remind investors that, under the terms of the collaborative framework announced on October 1, 2025, the FDA is conducting an expedited re-review of the partial clinical hold that currently restricts long-term clinical studies of tradipitant in motion sickness. The original target completion date was November 26, 2025. At the FDA's request—and with Vanda's assent—the target completion date has been extended to December 5, 2025 to accommodate recent personnel and leadership transitions within the Center for Drug Evaluation and Research (CDER). All other provisions of the collaborative framework remain unchanged. We remain cautiously optimistic that the agency shall either waive the requirement for long-term clinical studies of tradipitant to support approval in the motion sickness indication or remove the partial clinical hold, allowing such studies to be conducted."

For an analyst ratings summary and ratings history on Vanda Pharmaceuticals click here. For more ratings news on Vanda Pharmaceuticals click here.

Shares of Vanda Pharmaceuticals closed at $5.36 yesterday.

You May Also Be Interested In

• Freedom Broker Upgrades Satellogic, Inc. (SATL) to Buy, 'Growth quality is improving'
• Jana Builds Bigger Stake In Fintech Alkami And Pushes For Sale - Bloomberg
• Fortune Brands Innovations (FBIN) call put ratio 10.7 calls to 1 put with a focus on 3700 contracts of July 55 calls, share price up 10.7%